Live News EQUITY FLASH L impact Oct 27, 2026, 06:05 AM UTC Basilea to Initiate Phase 2/3 Study in Mid-2027 Basilea Pharmaceutica plans to initiate a Phase 2/3 study for ceftibuten-ledaborbactam in mid-2027. SquawkNews Desk